Understanding the glioblastoma tumor biology to optimize Photodynamic Therapy: From molecular to cellular events

MARIA L VILCHEZ; LUIS E IBARRA; LAURA N MILLA SANABRIA; MATIAS CAVERZAN

JOURNAL OF NEUROSCIENCE RESEARCH

WILEY-LISS, DIV JOHN WILEY & SONS INC

Lugar: New York; Año: 2021

0360-4012

Photodynamic Therapy (PDT) has recently gained attention as an alternative treatmentof malignant gliomas. Glioblastoma (GBM) is the most prevalent within tumors of thecentral nervous system (CNS). Conventional treatments for this CNS tumor includesurgery, radiation, and chemotherapy. Surgery is still being considered as the treatmentof choice. Even so, the poor prognosis and / or recurrence of the disease after applyingany of these treatments highlight the urgency of exploring new therapies and / orimproving existing ones to achieve the definitive eradication of tumor masses andremaining cells. PDT is a therapeutic modality that involves the destruction of tumor cellsby reactive oxygen species (ROS) induced by light, which were previously treated witha photosensitizing agent (PS). However, in recent years, its experimental application hasexpanded to other effects that could improve overall performance against GBM. In thecurrent review, we revisit the main advances of PDT for GBM management and also, therecent mechanistic insights about cellular and molecular aspects related to tumoralresistance to PDT of GBM